Abstract:Background Endometrial cancers (ECs) are one of the most common types of malignant tumor in females. Substantial efforts had been made to identify significantly mutated genes (SMGs) in ECs and use them as biomarkers for the classification of histological subtypes and the prediction of clinical outcomes. However, the impact of non-significantly mutated genes (non-SMGs), which may also play important roles in the prognosis of EC patients, has not been extensively studied. Therefore, it is essential for the discovery of biomarkers in ECs to further investigate the non-SMGs that were highly associated with clinical outcomes. Results For the 9681 non-SMGs reported by the mutation annotation pipeline, there were 1053, 1273 and 395 non-SMGs differentially expressed between the patient groups divided by the clinical endpoints of histological grade, histological type as well as the International Federation of Gynecology and Obstetrics (FIGO) stage of ECs, respectively. In the gene set enrichment analysis, the cancer-related pathways, namely neuroactive ligand-receptor interaction signaling pathway, cAMP signaling pathway and calcium signaling pathway, were significantly enriched with the differentially expressed non-SMGs for all the three endpoints. We further identified 23, 19 and 24 non-SMGs, which were highly associated with histological grade, histological type and FIGO stage, respectively, from the differentially expressed non-SMGs by using the variable combination population analysis (VCPA) approach and found that 69.6% (16/23), 78.9% (15/19) and 66.7% (16/24) of the identified non-SMGs had been previously reported to be correlated with cancers. In addition, the averaged areas under the receiver operating characteristic curve (AUCs) achieved by the predictive models with identified non-SMGs as predictors in predicting histological type, histological grade, and FIGO stage were 0.993, 0.961 and 0.832, respectively, which were superior to those achieved by the models with SMGs as features (averaged AUCs = 0.928, 0.864 and 0.535, resp.). Conclusions Besides the SMGs, the non-SMGs reported in the mutation annotation analysis may also involve the crucial genes that were highly associated with clinical outcomes. Combining the mutation status with the gene expression profiles can efficiently identify the cancer-related non-SMGs as predictors for cancer prognostic prediction and provide more supplemental candidates for the discovery of biomarkers.

Additional File 2: of Mutation Status Coupled with RNA-sequencing Data Can Efficiently Identify Important Non-Significantly Mutated Genes Serving As Diagnostic Biomarkers of Endometrial Cancer

Additional File 5: of Mutation Status Coupled with RNA-sequencing Data Can Efficiently Identify Important Non-Significantly Mutated Genes Serving As Diagnostic Biomarkers of Endometrial Cancer

Additional File 8: of Mutation Status Coupled with RNA-sequencing Data Can Efficiently Identify Important Non-Significantly Mutated Genes Serving As Diagnostic Biomarkers of Endometrial Cancer

Mutation Status Coupled with RNA-sequencing Data Can Efficiently Identify Important Non-Significantly Mutated Genes Serving As Diagnostic Biomarkers of Endometrial Cancer

Analysis of Long Non-Coding RNA Expression Profiles Using RNA Sequencing in Ovarian Endometriosis.

Additional File 7 of Single-cell Transcriptomic Analysis of Endometriosis Provides Insights into Fibroblast Fates and Immune Cell Heterogeneity

Additional File 3 of Circulating Tumor DNA As a Prognostic Marker in High-Risk Endometrial Cancer

Additional File 2 of Single-cell Transcriptomic Analysis of Eutopic Endometrium and Ectopic Lesions of Adenomyosis

Additional File 5 of A Novel Signature of Two Long Non-Coding RNAs in BRCA Mutant Ovarian Cancer to Predict Prognosis and Efficiency of Chemotherapy

Updated evaluation of clinicopathologic landscape in histopathologic subtypes of endometrial carcinoma with MMR gene mutation

Additional File 2 of A Novel Signature of Two Long Non-Coding RNAs in BRCA Mutant Ovarian Cancer to Predict Prognosis and Efficiency of Chemotherapy

Additional File 1 of Circulating Tumor DNA As a Prognostic Marker in High-Risk Endometrial Cancer

Additional File 2 of DNA Methylation Subtypes Guiding Prognostic Assessment and Linking to Responses the DNA Methyltransferase Inhibitor SGI-110 in Urothelial Carcinoma

Additional File 2 of Identification and Validation of a Six-Gene Signature Associated with Glycolysis to Predict the Prognosis of Patients with Cervical Cancer

Comprehensive Analysis of the Prognostic Signature of Mutation-Derived Genome Instability-Related lncRNAs for Patients With Endometrial Cancer

Additional File 4: of SMAD4 and NF1 Mutations As Potential Biomarkers for Poor Prognosis to Cetuximab-Based Therapy in Chinese Metastatic Colorectal Cancer Patients

Mutation in Homologous Recombination to Predict a Better Prognosis in Endometrial Cancer.

One-stop molecular classification of endometrial carcinoma using comprehensive next-generation sequencing

Additional File 1 of Synaptotagmin-like Protein 1 is a Potential Diagnostic and Prognostic Biomarker in Endometrial Cancer Based on Bioinformatics and Experiments

Exome Analysis Reveals Differentially Mutated Gene Signatures of Stage, Grade and Subtype in Breast Cancers.

Potential serum metabolites and long‐chain noncoding RNA biomarkers for endometrial cancer tissue